List of Tables
Table 1. Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Oseltamivir
Table 3. Key Players of Zanamivir
Table 4. Key Players of Peramivir
Table 5. Key Players of Laninamivir
Table 6. Global Neuraminidase Inhibitors Drug Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Neuraminidase Inhibitors Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Neuraminidase Inhibitors Drug Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Neuraminidase Inhibitors Drug Market Share by Region (2020-2025)
Table 10. Global Neuraminidase Inhibitors Drug Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Neuraminidase Inhibitors Drug Market Share by Region (2026-2031)
Table 12. Neuraminidase Inhibitors Drug Market Trends
Table 13. Neuraminidase Inhibitors Drug Market Drivers
Table 14. Neuraminidase Inhibitors Drug Market Challenges
Table 15. Neuraminidase Inhibitors Drug Market Restraints
Table 16. Global Neuraminidase Inhibitors Drug Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Neuraminidase Inhibitors Drug Market Share by Players (2020-2025)
Table 18. Global Top Neuraminidase Inhibitors Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuraminidase Inhibitors Drug as of 2024)
Table 19. Ranking of Global Top Neuraminidase Inhibitors Drug Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Neuraminidase Inhibitors Drug Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Neuraminidase Inhibitors Drug, Headquarters and Area Served
Table 22. Global Key Players of Neuraminidase Inhibitors Drug, Product and Application
Table 23. Global Key Players of Neuraminidase Inhibitors Drug, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Neuraminidase Inhibitors Drug Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2020-2025)
Table 27. Global Neuraminidase Inhibitors Drug Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2026-2031)
Table 29. Global Neuraminidase Inhibitors Drug Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Neuraminidase Inhibitors Drug Revenue Market Share by Application (2020-2025)
Table 31. Global Neuraminidase Inhibitors Drug Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Neuraminidase Inhibitors Drug Revenue Market Share by Application (2026-2031)
Table 33. North America Neuraminidase Inhibitors Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Neuraminidase Inhibitors Drug Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Neuraminidase Inhibitors Drug Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Neuraminidase Inhibitors Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Neuraminidase Inhibitors Drug Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Neuraminidase Inhibitors Drug Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Neuraminidase Inhibitors Drug Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Neuraminidase Inhibitors Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Neuraminidase Inhibitors Drug Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Neuraminidase Inhibitors Drug Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Neuraminidase Inhibitors Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2026-2031) & (US$ Million)
Table 48. Roche Company Details
Table 49. Roche Business Overview
Table 50. Roche Neuraminidase Inhibitors Drug Product
Table 51. Roche Revenue in Neuraminidase Inhibitors Drug Business (2020-2025) & (US$ Million)
Table 52. Roche Recent Development
Table 53. GSK Company Details
Table 54. GSK Business Overview
Table 55. GSK Neuraminidase Inhibitors Drug Product
Table 56. GSK Revenue in Neuraminidase Inhibitors Drug Business (2020-2025) & (US$ Million)
Table 57. GSK Recent Development
Table 58. Gilead Sciences Company Details
Table 59. Gilead Sciences Business Overview
Table 60. Gilead Sciences Neuraminidase Inhibitors Drug Product
Table 61. Gilead Sciences Revenue in Neuraminidase Inhibitors Drug Business (2020-2025) & (US$ Million)
Table 62. Gilead Sciences Recent Development
Table 63. Daiichi Sankyo Company Details
Table 64. Daiichi Sankyo Business Overview
Table 65. Daiichi Sankyo Neuraminidase Inhibitors Drug Product
Table 66. Daiichi Sankyo Revenue in Neuraminidase Inhibitors Drug Business (2020-2025) & (US$ Million)
Table 67. Daiichi Sankyo Recent Development
Table 68. AstraZeneca Company Details
Table 69. AstraZeneca Business Overview
Table 70. AstraZeneca Neuraminidase Inhibitors Drug Product
Table 71. AstraZeneca Revenue in Neuraminidase Inhibitors Drug Business (2020-2025) & (US$ Million)
Table 72. AstraZeneca Recent Development
Table 73. Pfizer Company Details
Table 74. Pfizer Business Overview
Table 75. Pfizer Neuraminidase Inhibitors Drug Product
Table 76. Pfizer Revenue in Neuraminidase Inhibitors Drug Business (2020-2025) & (US$ Million)
Table 77. Pfizer Recent Development
Table 78. Teva Company Details
Table 79. Teva Business Overview
Table 80. Teva Neuraminidase Inhibitors Drug Product
Table 81. Teva Revenue in Neuraminidase Inhibitors Drug Business (2020-2025) & (US$ Million)
Table 82. Teva Recent Development
Table 83. Bristol-Myers Squibb Company Details
Table 84. Bristol-Myers Squibb Business Overview
Table 85. Bristol-Myers Squibb Neuraminidase Inhibitors Drug Product
Table 86. Bristol-Myers Squibb Revenue in Neuraminidase Inhibitors Drug Business (2020-2025) & (US$ Million)
Table 87. Bristol-Myers Squibb Recent Development
Table 88. Sun Pharmaceutical Company Details
Table 89. Sun Pharmaceutical Business Overview
Table 90. Sun Pharmaceutical Neuraminidase Inhibitors Drug Product
Table 91. Sun Pharmaceutical Revenue in Neuraminidase Inhibitors Drug Business (2020-2025) & (US$ Million)
Table 92. Sun Pharmaceutical Recent Development
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
Table 96. Authors List of This Report
List of Figures
Figure 1. Neuraminidase Inhibitors Drug Picture
Figure 2. Global Neuraminidase Inhibitors Drug Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Neuraminidase Inhibitors Drug Market Share by Type: 2024 VS 2031
Figure 4. Oseltamivir Features
Figure 5. Zanamivir Features
Figure 6. Peramivir Features
Figure 7. Laninamivir Features
Figure 8. Global Neuraminidase Inhibitors Drug Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Neuraminidase Inhibitors Drug Market Share by Application: 2024 VS 2031
Figure 10. Hospital Pharmacy Case Studies
Figure 11. Retail Pharmacy Case Studies
Figure 12. Online Pharmacy Case Studies
Figure 13. Others Case Studies
Figure 14. Neuraminidase Inhibitors Drug Report Years Considered
Figure 15. Global Neuraminidase Inhibitors Drug Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Neuraminidase Inhibitors Drug Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Neuraminidase Inhibitors Drug Market Share by Region: 2024 VS 2031
Figure 18. Global Neuraminidase Inhibitors Drug Market Share by Players in 2024
Figure 19. Global Top Neuraminidase Inhibitors Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuraminidase Inhibitors Drug as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Neuraminidase Inhibitors Drug Revenue in 2024
Figure 21. North America Neuraminidase Inhibitors Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Neuraminidase Inhibitors Drug Market Share by Country (2020-2031)
Figure 23. United States Neuraminidase Inhibitors Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Neuraminidase Inhibitors Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Neuraminidase Inhibitors Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Neuraminidase Inhibitors Drug Market Share by Country (2020-2031)
Figure 27. Germany Neuraminidase Inhibitors Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Neuraminidase Inhibitors Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Neuraminidase Inhibitors Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Neuraminidase Inhibitors Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Neuraminidase Inhibitors Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Neuraminidase Inhibitors Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Neuraminidase Inhibitors Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Neuraminidase Inhibitors Drug Market Share by Region (2020-2031)
Figure 35. China Neuraminidase Inhibitors Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Neuraminidase Inhibitors Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Neuraminidase Inhibitors Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Neuraminidase Inhibitors Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Neuraminidase Inhibitors Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Neuraminidase Inhibitors Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Neuraminidase Inhibitors Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Neuraminidase Inhibitors Drug Market Share by Country (2020-2031)
Figure 43. Mexico Neuraminidase Inhibitors Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Neuraminidase Inhibitors Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Neuraminidase Inhibitors Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Neuraminidase Inhibitors Drug Market Share by Country (2020-2031)
Figure 47. Turkey Neuraminidase Inhibitors Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Neuraminidase Inhibitors Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Neuraminidase Inhibitors Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Roche Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2020-2025)
Figure 51. GSK Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2020-2025)
Figure 52. Gilead Sciences Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2020-2025)
Figure 53. Daiichi Sankyo Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2020-2025)
Figure 54. AstraZeneca Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2020-2025)
Figure 55. Pfizer Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2020-2025)
Figure 56. Teva Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2020-2025)
Figure 57. Bristol-Myers Squibb Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2020-2025)
Figure 58. Sun Pharmaceutical Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2020-2025)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
